Sunvozertinib
- Generic Name
- Sunvozertinib
- Indication
用于既往经含铂化疗治疗时或治疗后出现疾病进展，或不耐受含铂化疗，并且经检测确认存在表皮生长因子受体（EGFR）20号外显子插入突变的局部晚期或转移性非小细胞肺癌（NSCLC）的成人患者。
Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 180
- Registration Number
- NCT05559645
- Locations
- 🇨🇳
Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Beijing, Beijing, China
Assessing the Safety, Tolerability and Pharmacokinetics(PK) of DZD9008 and the Effect of Low-fat Meal on PK of DZD9008 in Healthy Adult Participants
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2022-06-02
- Lead Sponsor
- Dizal Pharmaceuticals
- Target Recruit Count
- 78
- Registration Number
- NCT04909242
- Locations
- 🇺🇸
PRA Health Sciences, Lenexa, Kansas, United States
Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)
- First Posted Date
- 2019-11-01
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Dizal Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT04148742
- Locations
- 🇨🇳
Jiangsu Province Hospital - Haematology, Nanjing, China
🇨🇳Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Nanjing, China
Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer with EGFR or HER2 Mutation (WU-KONG1)
- First Posted Date
- 2019-06-04
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Dizal Pharmaceuticals
- Target Recruit Count
- 315
- Registration Number
- NCT03974022
- Locations
- 🇮🇹
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - IRST IRCCS, Meldola, Italy
🇯🇵Okayama University Hospital, Okayama-Shi, Japan
🇪🇸Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath